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Abstract: An accurate, precise, and simple spectrophotometric method is proposed for the determination of the
antithyroid drug carbimazole using ruthenium(III) chloride. This method is based on the formation at room temperature
of a stable yellow-colored complex with λmax 370 nm. The method has a Beer’s law range of 7.81 to 1.95 × 10 2 µ g mL −1 ,
molar absorptivity coeﬃcient ε = 1.519 × 10 3 L mol −1 cm −1 , and correlation coeﬃcient of 0.997. The metal:ligand
(M:L) ratio of the complex was confirmed by the mole ratio and Job’s method of continuous variation, suggesting a 1:2
stoichiometry. The formed carbimazole:Ru(III) complex was confirmed by spectral studies, including Fourier transform
infrared, nuclear magnetic resonance, electron spin resonance, magnetic susceptibility, thermal analysis, and powder–
X-ray diﬀraction. Our method could be adopted for routine analysis of carbimazole, due to its ease, aﬀordability, and
eﬀectiveness.
Key words: Carbimazole, pharmaceutical, detection, Ru(III), Fourier transform infrared, spectrophotometric

1. Introduction
Carbimazole (CBZ) (Figure 1), ethyl 3-methyl-2-thioxo-4-imidazoline-1-carboxylate, is used to treat hyperthyroidism by reducing the intake of iodine. It also reduces the formation of diiodotyrosine and hence thyroxine.
Carbimazole, upon absorption into the body, is converted into its active form, methimazole, which prevents the
coupling of the thyroid peroxidase enzyme and iodination of the tyrosine residues on thyroglobulin, 1 thereby
reducing the production of the thyroid hormones T3 and T4 (thyroxine).

Figure 1. Structure of carbimazole.

Thyroid disease has become a serious public health problem in several countries; therefore, detection
of its drugs has become a prime clinical consideration. For this reason, several analytical procedures have
∗ Correspondence:
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been developed for the determination of carbimazole. These methods include a colorimetric method using
dichromate and molybdate for the assay of carbimazole in drug formulations; 2 bromometric determination
using N-bromosuccinimide and methyl red as an indicator; 3 a spectrophotometric method utilizing potassium
dichromate, sulfuric acid, and heating at 90

◦

C for 25 min; 4 and determination of carbimazole in tablet

form with iodine azide. 5 Apart from these routine analyses, several tedious methods have also been reported,
including the determination of carbimazole by first and third derivative spectrophotometry; 6 a flow-injection
method using Pd(II) with λ max of 325 nm; 7 a flow-injection with chemiluminescence detection of carbimazole
in pharmaceutical samples; 8 a spectrophotometric and spectrodensitometric method based on the reaction
with potassium bromate in bromide solution having λ max of 517 nm; and densitometric evaluation of thinlayer chromatograms of carbimazole at 291 nm. 9 Hydrolysis of carbimazole was studied by polarography and
spectrophotometry. 10 Carbimazole was studied by voltammetry and polarography on a mercury electrode. 11 A
reversed phase HPLC method was developed for carbimazole determination in bulk drugs and formulations. 12
Fourier transform infrared (FTIR), FT-Raman, and UV-Vis techniques and quantum chemical calculation of
carbimazole have also been reported. 13
This literature survey indicates that not much work has been done regarding the possible determination
of carbimazole using metals. We were therefore prompted to investigate the use of metals, such as ruthenium,
which provide a wide range of oxidation states and are relatively nontoxic. 14,15 Spectrophotometry is an eﬀective
and widely used technique, so a combination of both spectrophotometry and metal complexation could result
in an easy and simple determination method for carbimazole in tablet form.
2. Results and discussion
2.1. Optimization of the reaction conditions
Figures 2a and 2b show the UV-visible spectrum of carbimazole and its Ru(III) complex. Good results were
achieved by optimizing the reaction conditions by varying the temperature, pH, and time. The eﬀect of
temperature was studied by maintaining the temperature range from 25 ◦ C to 80 ◦ C with a thermostat.
An increase in temperature decreased the absorbance and color intensity (Figure 3), so room temperature (25
◦

C) was considered appropriate for maximum color intensity; all subsequent experiments were carried out at

25 ◦ C ( ± 5 ◦ C).
Carbimazole:Ru

(III) Complex

Absorbance

Absorbance

Carbimazole

325

480
Wavelength

Wavelength

Figure 2. a, b) UV-Vis spectrum of carbimazole and its Ru(III) complex.
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The eﬀect of pH was tested to determine whether the color intensity or absorbance of the formed
carbimazole:Ru(III) complex would decrease in response to pH changes. Hydrochloric acid was used to acidify
the solution (pH 3–4) and sodium hydroxide was used to raise the pH (pH 9–10).
The time required for complexation was studied by measuring the absorbance of a sample solution against
a blank solution at diﬀerent time intervals from 5 to 60 min (Figure 4). The time required for the complexation
was 20 min at λmax of 370 nm. No extreme change in the color intensity was observed even after 12 h.
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Figure 3. Eﬀect of temperature ( ◦ C) on the absorbance

Figure 4. The time course for complexation.

of the carbimazole:Ru(III) complex.

2.2. Stoichiometry
The stoichiometry of the complex was studied by Job’s method of continuous variation according to Ragehy et
al. 16 (Figure 5) and the mole ratio method (Figure 6).
Job`s Method of Continuous Variance of Carbimazole :Ru (III)
Complex
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Figure 5. Job’s method of continuous variation.
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Mole Ratio Plot of Caribimazole:Ru (III) Complex
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Figure 6. Mole ratio graph of carbimazole:Ru(III) complex.

Job’s method was conducted by preparing a series of solutions with a constant total volume of metal ion
Ru(III) and ligand (drug carbimazole). Here, the sum of the total analytical concentration of the complexing
agent (drug carbimazole) Cx and metal ion Ru(III) Cm was held constant and only their ratios were varied.
The absorbance of each solution mixture was measured at the λmax of the complex (370 nm). The
absorbance and mole fraction of the ligand C X /C were then presented graphically. The sides of the curve
were extrapolated to their point of intersection (n). Composition of the Ru(III):carbimazole complex was then
calculated as 1:2 as follows.

n =CX /Cm = x/1 − x
=0.34/1 − 0.34
Cx/Cm =0.5 = 1/2
2CX =Cm
M : L =1 : 2
By contrast, the mole ratio method was conducted by preparing a series of solutions in which the
concentration of one reactant [metal ion Ru(III)] was kept constant and the concentration of the other (the
carbimazole ligand) was varied. The absorbance of each solution was measured at 370 nm.
A graph drawn between absorbance and the mole ratio of the reagent gives a straight line with a positive
slope from the origin up to mole ratio value two and then becomes horizontal. This shows that the metal has
been consumed completely at a mole ratio of two and that further addition of ligand produces no additional
complexation. Thus, the composition of the complex was 1:2 for the Ru(III):carbimazole complex as determined
by the mole ratio method.
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2.3. Stability constant of the complex
The stability formation constant (Kf ) of the carbimazole:Ru(III) complex was evaluated according to a previous
study. 17 The color intensity and absorbance were constant for a maximum of 12 h. The stability constant can
be calculated from the following equation:
Kf = {

A
Am
(1−A)
Am

n n
}n−1 C n

where A and A m are the absorbance and maximum absorbance obtained from Job’s method, n is the ratio of
carbimazole:Ru(III), C is the molar concentration of carbimazole, and K f is the stability formation constant,
which was determined as 2.1 for the carbimazole:Ru(III) complex.
2.4. Analytical parameters
The linearity of the complex formation was evaluated using Beer’s law and the graph of concentration versus
absorbance (Figure 7), which indicated a good linearity range from 7.81 to 1.95 × 10 2 µ g mL −1 , with molar
absorptivity ( ε) = 1.519 × 10 3 L mol −1 cm −1 . The linear regression equation for the carbimazole:Ru(III)
complex was determined as follows (Table 1):

Figure 7. Beer–Lambert law plot for the carbimazole:Ru(III) complex.

Y = 6.01 × 10−3 + 1.09 × 10−2
The correlation coeﬃcient r was 0.99, slope b = 1.09 × 10 −2 , and intercept a = 6.031 × 10 −3 . The relative
standard deviation (RSD) was 1.89, LOD and LOQ were respectively found to be 1.83 µ g mL −1 and 5.53 µ g
mL −1 , and the standard analytical error was 0.763 for the carbimazole:Ru(III) complex. The present method
was compared with the reported methods (Table 2) and was found to be more accurate and precise.
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Table 1. Microdetermination of carbimazole as its Ru(III) complex.

S. no.

Weight taken

Weight found

Standard

Coeﬃcient of

Regression Eq.*

(in µg)

(in µg)

deviation

variation

statistical data

1

7.81

8.98

3.88 × 10−02

4.29 × 10−01

2

1.56 × 10+01

1.70 × 10+01

2.78 × 10−02

1.69 × 10−01

3

2.34 × 10+01

2.42 × 10+01

2.92 × 10−02

1.20 × 10−01

4

3.12 × 10+01

3.22 × 10+01

3.38 × 10−02

1.05 × 10−01

5

3.91 × 10

+01

4.06 × 10

5.45 × 10

−02

−01

6

4.69 × 10

+01

4.75 × 10

1.28 × 10

−02

7

5.47 × 10

+01

5.59 × 10

2.30 × 10

−02

8

6.25 × 10

+01

6.33 × 10

1.10 × 10

−02

9

7.03 × 10+01

7.09 × 10+01

2.55 × 10−02

3.57 × 10−02

10

7.81 × 10+01

7.99 × 10+01

1.91 × 10−02

2.40 × 10−02

LOQ = 5.53

11

8.59 × 10+01

8.71 × 10+01

2.30 × 10−02

2.64 × 10−02

µg mL−1

12

9.37 × 10+01

9.51 × 10+01

1.69 × 10−02

1.77 × 10−02

13

1.02 × 10+02

1.02 × 10+02

3.31 × 10−02

3.24 × 10−02

14

1.09 × 10+02

1.11 × 10+02

1.10 × 10−02

9.96 × 10−03

15

1.17 × 10+02

1.18 × 10+02

4.18 × 10−02

3.54 × 10−02

16

1.25 × 10+02

1.26 × 10+02

6.38 × 10−03

5.07 × 10−03

17

1.33 × 10+02

1.35 × 10+02

5.74 × 10−02

4.28 × 10−02

18

1.41 × 10+02

1.41 × 10+02

2.21 × 10−02

1.56 × 10−02

19

1.48 × 10+02

1.50 × 10+02

2.55 × 10−02

1.70 × 10−02

20

1.56 × 10+02

1.57 × 10+02

1.69 × 10−02

1.07 × 10−02

21

1.64 × 10+02

1.64 × 10+02

4.46 × 10−02

2.70 × 10−02

22

1.72 × 10+02

1.73 × 10+02

2.92 × 10−02

1.69 × 10−02

23

1.80 × 10+02

1.81 × 10+02

3.19 × 10−02

1.77 × 10−02

24

1.87 × 10+02

1.89 × 10+02

6.38 × 10−03

3.38 × 10−03

25

1.95 × 10+02

2.05 × 10+02

2.30 × 10−01

1.11 × 10−01

+01
+01
+01
+01

1.36 × 10

−02

2.68 × 10

−02

4.11 × 10

LOD = 1.83
µg mL−1
Slope
b = 1.09 × 10−2

−02

1.74 × 10

Intercept
a = 6.031 × 10−3

Correlation
coeﬃcient
r = 0.99

*Summation of five determinations.

2.5. Spectral study of the carbimazole:Ru(III) complex
2.5.1. FTIR study
The FTIR spectra were recorded in the range of 4000–400 cm −1 using a 1:3 ratio of KBr powder. The spectrum
of carbimazole shows a sharp band at 1203 cm −1 (Figure 8a), which is assigned to the presence of the C= S
group. This group is missing in the complex spectrum, thereby aﬃrming the involvement of the thione group
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Table 2. Comparison of present work with reported methods.
Reagent used

Iodine-azide
(TLC and HPTLC)

Carbimazole

Pd(II) catalyzed with
neutral red and
hypophosphite ion
Cu(II)-catalyzed
chemiluminescence
(CL) reaction
Palladium(II)catalyzed reaction
between the pyronine
G and hypophosphite
ions
(kinetic determination)
Ru(III)
(spectrophotometer)

Linear range
(µg mL–1)

LOD

20–200 µL

0.08 nmol
for TLC
and 0.04
nmol for
HPTLC

0.04–0.3 ppm

0.02 ppm

Pure and
tablets

26

3–120 mg L–1

-

Tablets

8

0.04–0.70 µg
mL–1

-

Pharmaceuti
cals, animal
feed, and
animal livers

27

0.02–1.78 µg
mL–1

1.83

Tablets

Present
method

Application

Tablets

Reference

5

with the Ru(III) ion. The FTIR spectrum of carbimazole also shows a band at 1699 cm −1 associated with the
thioimidazole ring. The decrease and alteration of this band to 1658 cm −1 in the carbimazole:Ru(III) complex
(Figure 8b) indicates the involvement of ring N in the bonding with the Ru(III) ion.
Two sharp bands appear at 1428 cm −1 and 1312 cm −1 in the carbimazole spectrum, 18 associated with
the presence of C =O-O-C stretching. These two bands are very much reduced in the spectrum of the complex,
indicating the degradation of the ester group attached to the fifth N atom.
Bands at 929 cm −1 and 801 cm −1 are attributed to the C-H band (oop) 19 mode of the aromatic ring,
which is reduced to 917 cm −1 and 872 cm −1 in the carbimazole:Ru(III) complex, suggesting high strain due
to participation of sulfur and nitrogen groups in binding. A wide array at 3414 cm −1 is allocated to OH strain
for the lattice water, 20 which aﬃrms the existence of H 2 O linked with the metal (M) ion through a dative
bond. An intermediate band at 460 cm −1 associated with Ru-N strain is frequently found in Ru–xylenol. 21
The strength of the M-N bond suggests an electrostatic nature; if this bond has a lower frequency, then it
features ionic behaviour. 22 Similarly, an average sized band at 420 cm −1 is assigned to the Ru–sulfur region.
2.5.2.

1

H NMR study

The 1 H NMR spectra were recorded using D 2 O CDCl 3 as a solvent and tetramethylsilane (TMS) as an internal
standard. The 1 H NMR spectrum of carbimazole (Figure 9a) shows a sharp signal triplet at 1.2 ppm, aﬃrming
the CH 3 group of ethyl acetate. This peak completely disappears in the 1 H NMR spectrum of the complex,
indicating the elimination of the ethyl acetate group in acidic medium in the complex.
A sharp and high intensity quartet at 4.30 ppm in the carbimazole spectrum is attributed to the CH 2
group of ethyl acetate. This peak completely disappears in the spectrum of the complex, confirming the removal
1001
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Figure 8. a, b) FTIR spectrum of carbimazole and its Ru(III) complex.

of ethyl acetate from carbimazole in an acidic medium and leaving behind the N-ring, which can easily bind
Ru(III) ions. The removal of the ethyl acetate group can also be confirmed by 13 C NMR, but the 1 H NMR
result is more accurate in the case of carbimazole as it gives clear information about hydrogen removal and the
eﬀect of the other H atom.
The HC=CH group of the imidazole ring is assigned at 7.38 and 6.8 ppm in the carbimazole spectrum
and shows no change in the spectrum of the complex.
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Figure 9. a, b)

1

H NMR spectrum of carbimazole and its Ru(III) complex.

A broadening of the peak observed in the region of 3–4 ppm accounts for the presence of an amino group.
These amino groups have exchangeable H, capable of exchanging protons with the solvent D 2 O to form DOH.
Consequently, a crest arises at 4.2 ppm in the carbimazole:Ru(III) complex (Figure 9b). A peak of coordinated
water can also be observed in the region of 3.5 ppm, as well as an aromatic N-CH 3 group, which also gives a
1003
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singlet peak in the region of 3.0–4.0 ppm. All these peaks get intermixed with one another and result in a broad
band in the spectrum of the complex.
The FTIR and 1 H NMR data indicate that the binding of carbimazole with the Ru(III) ion takes place
through sulfur and nitrogen functional groups.
2.5.3. ESR study
Scanning of the X-band in the electron spin resonance (ESR) spectrum of carbimazole (Figure 10a) revealed no
resonance peak, thereby confirming its diamagnetic nature. The X-band for the carbimazole:Ru(III) complex
(Figure 10b) gives an ESR signal at 1620 Gauss.
Calculation of Lande’s G-factor (splitting factor): 23,24
[
]
∆H
g sample = 20023 1 −
H
where ∆H is the width between deflection points on the derivative absorption curve.
H =magnetic field
gStd =Lande’s factor for free electrons
[
]
∆H
g sample =20023 1 −
H
[
]
300
g sample =20023 1 −
1620
gqStd =1.631
The value of g obtained for the complex was quite low when compared to the g value of free electrons. This
indicates the covalent nature of the complex owing to the d 5 electronic configuration.
2.5.4. Magnetic susceptibility measurement of the carbimazole:Ru(III) complex
The magnetic properties of the carbimazole:Ru(III) complex were determined using vibrating sample magnetometry (VSM). The magnetic moment ( µ) value obtained was substituted into the following equation to
calculate µef f .
Xm =

Molecular Weight × slope × 1.1128 × 10−21 B.M.
Sample weight × 0.9273 × 10−20
where slope =

µ( magnetic moment in emu)
H(applied field in Gauss)

√
and µef f = 2.828 X m × temperature
The value of µef f was 1.65 BM, which is slightly lower than the expected value of 2.10 BM for a Ru(III) low
spin complex. The decrease in the µef f value in the present case may be due to the lower symmetry ligand
fields and electron delocalization. The value of µef f indicates that the number of unpaired electrons present
in the central metal ion is equal to one. The hybridization state of the central metal ion Ru +3 has the valence
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Figure 10. a, b) ESR spectra of carbimazole and its Ru(III) complex.

shell electronic configuration 4d 5 (t 52g , eg 0 ), which is d 2 sp 3 . Thus, ruthenium in its + 3 oxidation state
has a d 5 configuration and it forms low spin hexa-coordinated complexes with one unpaired spin. Thus, the
carbimazole:Ru(III) complex is an inner orbital complex having octahedral geometry.
2.5.5. Thermogravimetric (TG) study
Both TG and DTG curves reveal a three-step decomposition process for the carbimazole:Ru(III) complex (Figure
11a) in the range of 34.15–800.8 ◦ C. The first step shows a weak and small peak (T DT G 100 ◦ C) assigned to
the slow decomposition of one lattice water molecule and one chlorine atom present outside the coordination
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sphere, with weight loss of 0.77%. The second step, in contrast, is sharp and strong (T DT G 223.54

◦

C) and

accounts for the rapid removal of a coordinated water molecule attached to the Ru(III) ion, with a weight loss
of 12.81%. The third step is small and weak (T DT G 349.95 ◦ C) and is assigned to the slow degradation of the
drug moiety where C-C and C-H bonds begin to decompose, with a weight loss of 1.195%. Decomposition of
the drug moiety continues up to 800 ◦ C, leaving a final residue of elemental carbon and Ru(III). These results
have also been confirmed by diﬀerential thermal analysis (DTA) (Table 3).

Figure 11. a, b) TG and DTA of the carbimazole:Ru(III) complex.
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Table 3. Characteristic parameters of thermal decomposition.

Compound

Step

Carb:Ru(III)

1
2
3

TG weight loss
Found (%) Calculated (%)
0.79%
0.77%
12.83%
12.81%
1.196%
1.195%

Ti /◦ C

Tf / ◦ C

TDT G /◦ C

66.70◦
200.0◦
300.0◦

146.62◦
300.0◦
349.95◦

100◦
223.54◦
419.8◦

Carb = Carbimazole.

2.5.6. Diﬀerential thermal analysis
2.5.6.1. Endotherm at 100

◦

C

A moderate endothermic band (Figure 11b) starting at 66.70 ◦ C and completing at 146.62
loss of a coordinated water molecule. This was also suggested from the TGA curve.
2.5.6.2. Exotherm from 200

◦

◦

C to 300

◦

C confirmed the

C

◦

The exotherm band from 200 C up to 300 ◦ C is due to removal of coordinated water from the axial
position. Here, a coordinated water molecule, when detached from the complex, decreases the Ru(III) metal
ion. Consequently, Ru(III) is oxidized from its coordinated state.
2.5.6.3. Endotherm from 400

◦

C to 600

◦

C

◦

A broad endotherm in the region from 400 C to 600 ◦ C was assigned to the breakdown of the drug moiety.
These changes continue up to 800 ◦ C, where the entire drug moiety is converted into its constituents, i.e.
elemental carbon and residues of Ru(III).
The TGA and DTA results indicate the following decomposition steps:
[C8 H10 N4 S2 Ru(H2 O) 2 ].Cl
−H2 O TDT G 100◦ C
- Cl


[C8 H10 N4 S2 Ru (H2 O)]
-H2 O TDT G 250

◦

C


[C8 H10 N4 S2 Ru]
349.95 ◦ C – 800

◦

C


Ru(III) + Elemental carbon
2.5.7. Powder X-ray diﬀraction (PXRD) study
The powder X-ray diﬀractograms of Ru(III) (Figure 12a), carbimazole (Figure 12b), and its Ru(III) complex
(Figure 12c) were obtained with the help of the Diﬀraction Plus basic evaluation package (EVA 10.0) of Bruker
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Figure 12. a, b, c) Diﬀractogram of Ru(III), carbimazole, and the carbimazole:Ru(III) complex.
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Advanced X-ray Solutions. The data obtained using this software were further refined using Topaz software
(version 10.0) to obtain lattice parameters, Miller indices, and crystallite size. Prediction of the diﬀractogram
was done by matching the data with the JCPDS files (Joint Committee of Powder Diﬀraction Standards).
H3C

CH3

N

OH2

S

+

N

Ru
Cl

O

N
OH2

Cl

Carbimazole

C

S

Carbimazole

+

N
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H2O

O

C

O

O
H2C

CH2

CH3

H3C

H2O
H3C
CH3

N
S

N

S

N

Ru

.Cl
N

.H2O

H2O

+

2HCl

+

2 CH3CH2COOH

Figure 13. Proposed model for the carbimazole:Ru(III) complex.

The data obtained using the Topaz software shows that carbimazole has space group P2, R-Bragg 21.882,
crystallite size 526.83 nm, and Miller indices (Table 4) with monoclinic crystal structure, whereas its complex
has space group Pbma, R-Bragg 26.608, crystallite size 209 nm, and Miller indices (Table 4) with orthorhombic
crystal structure, as confirmed by the following axial distance and axial angles:
Carbimazole
a (A◦ ) = 12.075 α = 90◦
b (A◦ ) = 11.082 β = 117.762◦
c (A◦ ) = 15.750 γ = 90◦

Carbimazole:Ru(III) complex
a (A◦ ) = 9.873 α = 90◦
b (A◦ ) = 14.642 β = 90◦
c (A◦ ) = 12.531 γ = 90◦

The powder X-ray diﬀractogram of carbimazole showed ten peaks with an angle range from 3 ◦ to 100 ◦ .
Two high intensity peaks in the carbimazole diﬀractogram were assigned to:
(2 θ) 10.355 ◦ , d = 8.535 A ◦ , Intensity = 260, Miller indices (hkl) = 111
(2 θ) 16.603 ◦ , d = 5.335 A ◦ , Intensity = 210, Miller indices (hkl) = 121
1009

SHARMA et al./Turk J Chem

Table 4. Powder X-ray diﬀraction data of carbimazole and its Ru(III) complex.

Carbimazole
S. no. d-value
1
8.535 A◦
2
6.962 A◦
3
5.335 A◦
4
4.405 A◦
5
4.146 A◦
6
3.713 A◦
7
3.451 A◦
8
3.220 A◦
9
2.683 A◦
10
2.419 A◦

2θ
10.355◦
12.704◦
16.603◦
20.142◦
21.415◦
23.945◦
25.795◦
27.673◦
33.366◦
37.137◦

I
260
95
220
55
25
71
15
32
45
20

hkl
111
002
121
201
222
311
032
3(-2)(-3)
423
425

Carbimazole: Ru
S. no. d-value
1
5.657
2
4.323
3
3.560
4
3.329
5
1.611
6
1.218

(III) Complex
2θ
I
15.651 22.5
20.523 38
24.987 24
32.846 33
57.093 28
78.452 24

hkl
211
102
411
342
628
4(10)5

whereas the remaining peaks were of medium and low intensity. These peaks were attributed to the presence
of the thio group and were missing in the carbimazole:Ru(III) diﬀractogram. Furthermore, a comparison of
the carbimazole diﬀractogram with the data reported in the literature indicated that carbimazole contains an
imidazole moiety that strongly resembles the methyl benzimidazole moiety [PDF No. 3-1753]. 25
The following are peaks found in common in both the carbimazole and benzimidazole motif:
(2 θ) 21.415 ◦ , d = 4.1463 A ◦ , Intensity = 25, Miller indices (hkl) = 222
(2 θ) 25.795 ◦ , d = 3.4510 A ◦ , Intensity = 15, Miller indices (hkl) = 032
(2 θ) 33.366 ◦ , d = 2.6832 A ◦ , Intensity = 45, Miller indices (hkl) = 423
These peaks were shifted in the diﬀractogram of carbimazole:Ru(III) as follows:
(2θ) 24.987 ◦ , d = 3.560 A ◦ , Intensity = 24, Miller indices = 411
(2θ) 32.846 ◦ , d = 3.329 A ◦ , Intensity = 7, Miller indices = 342
whereas the peak at ( θ) 21.415 ◦ disappeared, suggesting the involvement of the imidazole ring of
carbimazole in the complexation with the Ru(III) ion.
The peaks found in the diﬀractogram of carbimazole at
(2 θ) 12.704 ◦ , d = 6.962 A ◦ , Intensity = 95, Miller indices (hkl) = 002
(2 θ) 37.137 ◦ , d = 2.419 A ◦ , Intensity = 20, Miller indices (hkl) = 425
closely resembled those reported in the JCPDS File (PDF No. 37-0831), predicting the presence of an
acetate group in the drug moiety. On complexation, this acetate group was detached from the parent moiety
in acidic medium. Thus, these peaks were absent in the diﬀractogram of the complex.
Three new peaks were found in the diﬀractogram of the complex. These peaks were assigned to the
binding of Ru(III) with sulfur and nitrogen atoms. This binding was also confirmed from the diﬀractogram
data for pure trihydrated ruthenium trichloride (Figure 12a).
The PXRD data therefore suggest that carbimazole and its Ru(III) complex were crystalline in nature,
with monoclinic and orthorhombic crystal structures.
Thus, these study results support the following proposed complexation model for carbimazole and Ru(III).
1010

SHARMA et al./Turk J Chem

3. Experimental
UV-Visible spectra were recorded on a Unicam Helios spectrophotometer (Thermo, USA). FTIR spectra were
recorded on a Shimadzu 8100 FTIR spectrometer (Japan) at the Department of Chemistry, Rani Durgavati
University, Jabalpur, Madhya Pradesh, India.
1

H NMR spectra were obtained using a Varian 400 MHz spectrometer (USA) and D 2 O CDCl 3 as the

solvent, with tetramethylsilane (IIT Mumbai, India) as the internal standard. ESR spectra were recorded on a
Varian spectrometer (USA) in the scan range of 2000 Gauss (G) at room temperature, using tetracyanoethylene
as the marker (IIT Mumbai, India).
Thermogravimetric analysis (TG-DTA) was carried out at STIC Cochin University (Kerala, India) on a
PerkinElmer thermal analysis system under nitrogen atmosphere in the 0–800 ◦ C temperature range at a rate
of 20 ◦ C min −1 .
Powder XRD was performed on a Bruker Advance D8 Diﬀractometer (USA) at STIC Cochin University
(Kerala, India). The diﬀractograms were scanned in the range of 0–100 with a maximum angular speed of 30 ◦
s −1 using Cu ( λ = 1.5406 A ◦ ) as the X-ray source and a Si (Li) PSD detector.
3.1. Preparation of the ruthenium trichloride solution
A stock solution of ruthenium trichloride trihydrate (RuCl 3 · 3H 2 O) was prepared by dissolving an ampoule
containing 1.0 g of Ru(III) (John Baker Inc., USA) in 250 mL of 2 M HCl in double distilled water to produce
a volume of 1.0 L. The working solutions were made by dilution of this standard stock solution.
3.2. Preparation of carbimazole solution
Carbimazole tablets (brand name: Neomercazole) were obtained from Nicholas Piramal, Mumbai, India; each
tablet contained 10 mg of carbimazole. One hundred milligrams of carbimazole was weighed and thoroughly
mixed with 20 mL of distilled water, and the volume was made up to 100 mL by adding distilled water. The
resulting mixture was filtered through No. 42 Whatman filter paper to avoid impurities. Standardization of the
solution was done bromometrically. 3 Solutions of lower concentration were made by dilution of the standard
stock solution.
3.3. Procedure
To diﬀerent aliquots (from 0.7 to 20 mL of a 5.76 × 10 −4 M solution) of carbimazole were added equimolar
amounts of Ru(III) solution (molarity 5.84 × 10 −4 M). The solutions were allowed to stand for 20 min at room
temperature. Absorbance was then recorded at the λmax of the complex (370 nm) (Figure 2), which was found
to diﬀer from the λmax of carbimazole.
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